Japanese Astellas Pharma Executive Sentenced for Espionage in China Expected Release Next Month
On.cc · 2 SOURCESabout 1 hour ago2 MIN
Summary
A Japanese executive from pharmaceutical company Astellas Pharma is expected to be released from a Chinese prison in mid-December after completing a 3-year-6-month sentence for espionage-related charges. The man in his 60s was detained in Beijing in March 2023 while preparing to return to Japan, arrested in October 2023, and sentenced by the Beijing No. 2 Intermediate People's Court in July 2025. He did not appeal the verdict. The Japanese government had repeatedly requested his early release, but China declined. Upon his expected release in mid-December 2026, he is anticipated to be immediately repatriated to Japan.
Key Points
- Astellas Pharma executive detained in Beijing in March 2023 while preparing to return to Japan, accused of violating China's anti-espionage law
- The defendant was formally arrested in October 2023 and prosecuted in August 2024 before being sentenced in July 2025
- Beijing's No. 2 Intermediate People's Court sentenced him to 3 years and 6 months in prison; he chose not to appeal the verdict
- Japanese authorities have been seeking his early release since the case began, but Beijing rejected all such requests
- Upon completion of his sentence expected in mid-December, the executive is set to be immediately deported back to Japan
Why It Matters
The case highlights ongoing tensions between Japan and China over Beijing's expansive interpretation of national security laws, particularly the anti-espionage legislation that has increasingly targeted foreign nationals and multinational corporations operating in China . For Hong Kong readers, this case signals that China's enforcement of national security statutes extends beyond political dissidents to include ordinary business executives, potentially affecting how regional companies manage their operations and personnel in the mainland.
The case highlights ongoing tensions between Japan and China over Beijing's expansive interpretation of national security laws, particularly the anti-espionage legislation that has increasingly targeted foreign nationals and multinational corporations operating in China . For Hong Kong readers, this case signals that China's enforcement of national security statutes extends beyond political dissidents to include ordinary business executives, potentially affecting how regional companies manage their operations and personnel in the mainland.